Two AI acquisitions announced on November 17 and 18 come from very different worlds, HR software and genetic medicine. They buy the same kind of thing. Neither buyer needed a better model. Both bought the context that tells a model what a question actually means.
Workday announced at Workday Rising EMEA in Barcelona that it intends to acquire Honeydew, a semantic layer for AI and business intelligence. Terms weren’t disclosed. The deal should close in Workday’s fiscal fourth quarter, which ends January 31, 2027. Honeydew stores a company’s business definitions (what counts as headcount, for example, which can mean three different numbers to three departments) and compiles them into governed database queries. It picks the right definition based on who is asking and why, and it carries permissions along, so an agent can’t see data its user couldn’t. Workday will embed it in Workday Data Cloud and run it against live data rather than a stale copy in a warehouse.
The quotes are unusually frank. Honeydew’s CEO, David Krakov, says getting AI to write database queries was never the hard part. Workday’s CTO, Gabe Monroy, says models shouldn’t improvise financial calculations. The design reflects that. Business logic gets compiled into a deterministic query before the request reaches the model, instead of being stuffed into a prompt. Workday claims this means more accurate answers and fewer tokens. Those are vendor claims. The logic is sound, though. If you’re selling agents to CFOs, the agent can’t be allowed to guess what “revenue” means.
Astromech, a Dallas AI company co-founded by George Church and Ben Lamm that grew out of Colossal Biosciences, is buying Form Bio in an all-stock deal valued at $230 million. Form Bio, also a Colossal spinout, has raised more than $40 million and builds genomics foundation models and design tools for genetic medicines, with programs at Eli Lilly, Stanford, Taysha Gene Therapies and Solid Biosciences. Astromech, which has raised more than $60 million, models how living systems change, using genomic data across many species. The deal covers Form Bio’s IP, selected contracts and team. Form Bio co-founder Andrew Busey becomes Astromech’s Chief AI Officer.
The pitch is moving quality control upstream. Astromech’s models predict which DNA is conserved and functional; Form Bio’s tools design and test the constructs. Put together, the goal is to cut unwanted components out at the design stage instead of purifying them out later. In one Duchenne muscular dystrophy program, Form Bio says it raised full-genome content from 13% to 59% in under 30 days by redesigning a promoter.
A $230 million stock deal between two companies that came out of the same lab is partly a reshuffle, and the value is only as good as Astromech’s stock. Still, the two deals agree on where enterprise AI is going. Models are cheap now. Knowing what a company’s data means, or what a stretch of DNA does, is the scarce part, and that’s what got bought.